Opinion|Videos|May 28, 2024
NCCN Guidelines: Optimizing NSCLC Treatment with Concurrent Biomarker Testing
Key opinion leaders examine the current National Comprehensive Cancer Network (NCCN) guidelines regarding the utilization of liquid and tissue biopsies, highlighting the necessity for the NCCN to prioritize and recommend concurrent testing as the preferred approach over relying on a single liquid or tissue biopsy alone.
Advertisement
Episodes in this series
Advertisement
Related to this article
Phase 3 SAFFRON data support EU and Japanese filings for savolitinib plus osimertinib in EGFR-mutated NSCLC with MET overexpression or amplification.
RELATIVITY-1093 is comparing nivolumab and relatlimab plus chemotherapy vs pembrolizumab plus chemotherapy in PD-L1–positive nonsquamous NSCLC.
The FDA approved talazoparib plus enzalutamide in HRR-mutated prostate cancer, ivonescimab improved survival in biliary tract cancer, and more.
IBI363 plus bevacizumab extended progression-free survival vs docetaxel in patients with immunotherapy-resistant lung adenocarcinoma in a randomized phase 1b study.
Thoracic oncologists discuss HER2 testing, frontline treatment selection, and resistance mechanisms in HER2-altered non–small cell lung cancer.
Sac-TMT plus pembrolizumab prolonged PFS over chemoimmunotherapy in PD-L1–negative nonsquamous lung cancer.
Adjuvant pembrolizumab continued to extend DFS in resected stage IB to IIIA NSCLC, though OS did not differ from placebo.
Longer DeLLphi-304 follow-up showed sustained OS, PFS, and response durability with tarlatamab in second-line small cell lung cancer.
Advertisement
Advertisement
Trending on OncLive
1
Dr Hansen on the Potential Role of GPRC5D-Targeted CAR T-Cell Therapy in Myeloma
2
Camizestrant Approval Paves the Way for ctDNA-Guided Switching in Emergent ESR1-Mutated HR+/HER2– Advanced Breast Cancer
3
Belzutifan Plus Lenvatinib Raises New Sequencing Questions in Advanced RCC
4
EU, Japanese Approval Is Sought for Savolitinib Plus Osimertinib in MET-Driven EGFR-Mutated NSCLC
5